Invesco discloses 5% ADMA Biologics (ADMA) stake held for clients
Rhea-AI Filing Summary
Invesco Ltd. filed an amended Schedule 13G reporting beneficial ownership of 11,785,202 shares of ADMA Biologics Inc common stock, representing 5.0% of the class as of 12/31/2025. Invesco reports sole voting power over 11,085,226 shares and sole dispositive power over 11,785,202 shares.
The shares are held of record by clients of Invesco’s investment adviser subsidiaries, including Invesco Advisers, Inc., Invesco Asset Management Limited, and Invesco Capital Management LLC, with no single individual having more than 5% economic ownership. Invesco certifies the position is held in the ordinary course of business and not to influence control of ADMA.
Positive
- None.
Negative
- None.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What percentage of ADMA (ADMA) does Invesco Ltd. report owning?
Invesco Ltd. reports beneficial ownership of 5.0% of ADMA Biologics’ common stock. This stake corresponds to 11,785,202 shares held as of December 31, 2025, according to the amended Schedule 13G filing.
Is Invesco Ltd. seeking to influence control of ADMA (ADMA) with this stake?
Invesco certifies the ADMA shares were acquired and are held in the ordinary course of business. It states they were not acquired for the purpose of changing or influencing control of ADMA Biologics.
Which Invesco subsidiaries are associated with the ADMA (ADMA) holdings?
The filing identifies Invesco Advisers, Inc., Invesco Asset Management Limited, and Invesco Capital Management LLC as the relevant subsidiaries. These investment adviser entities hold ADMA shares on behalf of their clients.
What type of reporting person is Invesco Ltd. in the ADMA (ADMA) filing?
Invesco Ltd. is classified as a parent holding company or control person, indicated by the type code HC. The company is organized in Bermuda and files on behalf of its investment adviser subsidiaries.